Analyzing VYNE Therapeutics (NASDAQ:VYNE) and Skye Bioscience (NASDAQ:SKYE)

VYNE Therapeutics (NASDAQ:VYNE) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Risk & Volatility

VYNE Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Valuation and Earnings

This table compares VYNE Therapeutics and Skye Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$493,000.00	128.06	-$28.45 million	($0.86)	-4.98
Skye Bioscience	N/A	N/A	-$37.65 million	N/A	N/A

VYNE Therapeutics has higher revenue and earnings than Skye Bioscience.

Profitability

This table compares VYNE Therapeutics and Skye Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-6,896.55%	-43.73%	-38.55%
Skye Bioscience	N/A	-45.78%	-37.44%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for VYNE Therapeutics and Skye Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	0	0	2	0	3.00
Skye Bioscience	0	0	6	0	3.00

VYNE Therapeutics presently has a consensus price target of $6.88, suggesting a potential upside of 60.63%. Skye Bioscience has a consensus price target of $18.67, suggesting a potential upside of 508.03%. Given Skye Bioscience’s higher possible upside, analysts plainly believe Skye Bioscience is more favorable than VYNE Therapeutics.

Institutional and Insider Ownership

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 4.8% of VYNE Therapeutics shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

About Skye Bioscience

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.